Zevra Therapeutics Inc (ZVRA) Q3 2024: Everything You Need To Know Ahead Of Earnings [Yahoo! Finance]
Zevra Therapeutics, Inc. (ZVRA)
Company Research
Source: Yahoo! Finance
The consensus estimate for Q3 2024 revenue is $4.87 million, and the earnings are expected to come in at -$0.42 per share. The full year 2024's revenue is expected to be $23.41 million and the earnings are expected to be -$1.67 per share. More detailed estimate data can be found on the Forecast page Warning! GuruFocus has detected 8 Warning Signs with ZVRA. Over the past 90 days, revenue estimates for Zevra Therapeutics Inc ( NASDAQ:ZVRA ) for the full year 2024 have declined from $28.87 million to $23.41 million. For 2025, estimates have increased from $81.72 million to $97.97 million. Earnings estimates for the full year 2024 have declined from -$1.60 per share to -$1.67 per share, while for 2025, estimates have improved from -$0.63 per share to -$0.35 per share. In the previous quarter of 2024-06-30, Zevra Therapeutics Inc's ( NASDAQ:ZVRA ) actual revenue was $4.45 million, which beat analysts' revenue expectations of $4.356 million by 2.13%. Zevra Therapeutics Inc's ( NASDAQ
Show less
Read more
Impact Snapshot
Event Time:
ZVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVRA alerts
High impacting Zevra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVRA
News
- Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type CGlobeNewswire
- Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $25.00 to $23.00. They now have a "buy" rating on the stock.MarketBeat
- Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates [Yahoo! Finance]Yahoo! Finance
ZVRA
Earnings
- 11/12/24 - Miss
ZVRA
Sec Filings
- 11/14/24 - Form SCHEDULE
- 11/14/24 - Form SC
- 11/13/24 - Form 10-Q
- ZVRA's page on the SEC website